Data updated: May 26, 2026
QWO (collagenase clostridium histolyticum-aaes)
Dermatology
Approved 2020-07-06
1
Indication
--
Phase 3 Trials
5
Years on Market
Details
- Status
- Prescription
- First Approved
- 2020-07-06
- Routes
- SUBCUTANEOUS
- Dosage Forms
- SOLUTION
QWO Approval History
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2020 to 2020
What QWO Treats
1 FDA approvalsOriginally approved for its first indication in 2020 .
- Other (1)
📋
Clinical Trial Registry
2 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05309525 | LUX-EN-001 | Ph 4 | completed | Effect of Oral TXA on Buttock Bruising Post CCH Injections in Adult Females |
| NCT05026216 | DMRR-001 | Ph 4 | completed | To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite. |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
QWO FDA Label Details
Track QWO with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.